76.04
Edwards Lifesciences Corp stock is traded at $76.04, with a volume of 6.33M.
It is up +1.21% in the last 24 hours and up +6.74% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$75.13
Open:
$74.82
24h Volume:
6.33M
Relative Volume:
1.40
Market Cap:
$40.53B
Revenue:
$5.54B
Net Income/Loss:
$4.18B
P/E Ratio:
10.86
EPS:
7
Net Cash Flow:
$259.90M
1W Performance:
+6.31%
1M Performance:
+6.74%
6M Performance:
+9.60%
1Y Performance:
-13.60%
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
![]()
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
![]()
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-30-25 | Upgrade | Stifel | Hold → Buy |
Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
Jul-25-24 | Downgrade | Truist | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
May-22-24 | Upgrade | Citigroup | Neutral → Buy |
May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
May-30-23 | Resumed | Morgan Stanley | Overweight |
Mar-29-23 | Initiated | UBS | Neutral |
Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-06-22 | Downgrade | Stifel | Buy → Hold |
Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-26-22 | Initiated | Mizuho | Buy |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-13-22 | Initiated | Truist | Buy |
Apr-06-22 | Initiated | Wolfe Research | Outperform |
Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Feb-02-22 | Upgrade | UBS | Neutral → Buy |
Jan-27-22 | Reiterated | Citigroup | Buy |
Jan-27-22 | Reiterated | Evercore ISI | Outperform |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | Stifel | Buy |
Jan-27-22 | Reiterated | UBS | Neutral |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
Jul-30-21 | Reiterated | Deutsche Bank | Hold |
Jul-30-21 | Reiterated | Jefferies | Buy |
Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
Jul-30-21 | Reiterated | Oppenheimer | Outperform |
Jul-30-21 | Reiterated | Stifel | Buy |
Jul-30-21 | Reiterated | UBS | Neutral |
Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
Sep-11-20 | Initiated | Wolfe Research | Underperform |
Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-10-20 | Initiated | Oppenheimer | Outperform |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
Sep-23-19 | Initiated | Piper Jaffray | Overweight |
Jul-24-19 | Reiterated | BofA/Merrill | Buy |
Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-19 | Initiated | Deutsche Bank | Hold |
Nov-28-18 | Initiated | UBS | Neutral |
Oct-16-18 | Initiated | Barclays | Underweight |
Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks
Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Benzinga
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance
Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com
Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus
Edwards Lifesciences Reports Strong Q1 Growth - TipRanks
Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardiac Platform Success - GuruFocus
Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize
Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus
Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com
Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN
Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus
Edwards Lifesciences Reports First Quarter Results - TradingView
Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq
Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com
Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support? - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com Australia
Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - BioSpace
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa
Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech
Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - marketscreener.com
Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards wins CE mark for Sapien M3 transfemoral heart valve - MassDevice
Breakthrough: First-Ever Transcatheter Mitral Valve Replacement Gets CE Mark Approval - Stock Titan
Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - marketscreener.com
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - marketscreener.com
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):